Regulatory News Hegseth orders testosterone testing for troops as FDA moves to loosen TRT prostate cancer warningsExperts caution the move amounts to a “huge, unregulated, natural experiment” July 24, 2026Vol.52 No.29By Claire Marie Porter
Regulatory News FDA final guidance on psychedelics opens the door to psycho-oncology researchGuidance permits treatment without psychotherapy, alarming scientists, advocates July 17, 2026Vol.52 No.28By Sara Willa Ernst
Regulatory News OMB proposal to sideline peer review sparks widespread oppositionNearly 500,000 public comments flood in—here are some highlights July 17, 2026Vol.52 No.28By Claire Marie Porter
Regulatory News To keep the early clinical trial enterprise in the U.S., HHS pledges to simplify regulatory requirements June 26, 2026Vol.52 No.25By Paul Goldberg
Regulatory News Is psilocybin heading to a cancer clinic near you?Reversing Nixon-era taboo, Trump orders FDA to fast-track psychedelics and ARPA-H to fund research June 18, 2026Vol.52 No.24By Sara Willa Ernst
Regulatory News After a year-long reign over tumult at FDA, Makary heads for the exitFruit-flavored e-cigs were the final blow for the commissioner May 15, 2026Vol.52 No.19By Claire Marie Porter
Regulatory News Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC May 08, 2026Vol.52 No.18By Jacquelyn Cobb
Regulatory News FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients“Patients are owed another review.” May 01, 2026Vol.52 No.17By Sara Willa Ernst
Health EquityRegulatory News Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancerA kit for at-home unsupervised self-collection clears FDA finish line April 17, 2026Vol.52 No.15By Claire Marie Porter
Regulatory News Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again) March 13, 2026Vol.52 No.10By Claire Marie Porter
